Members of the Celyad Oncology leadership team will provide an overview of the recent breakthroughs in the R&D pipeline including insights into new preclinical allogeneic CAR T assets using shRNA technology, the Company’s in-house cell therapy manufacturing capabilities and updates on key clinical programs. These updates will include the shRNA-based allogeneic candidate CYAD-211 for relapsed/refractory multiple myeloma and the industry-leading allogeneic candidate CYAD-101 for metastatic colorectal cancer in advance of the launch of the KEYNOTE-B79 clinical collaboration trial with Merck.